| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C19orf52 |
| Uniprot No | Q9BSF4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-260aa |
| 氨基酸序列 | MAAAALRRFWSRRRAEAGDAVVAKPGVWARLGSWARALLRDYAEACRDASAEARARPGRAAVYVGLLGGAAACFTLAPSEGAFEEALLEASGTLLLLAPATRNRESEAFVQRLLWLRGRGRLRYVNLGLCSLVYEAPFDAQASLYQARCRYLQPRWTDFPGRVLDVGFVGRWWVLGAWMRDCDINDDEFLHLPAHLRVVGPQQLHSETNERLFDEKYKPVVLTDDQVDQALWEEQVLQKEKKDRLALSQAHSLVQAEAPR |
| 分子量 | 55.6 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C19orf52蛋白的模拟参考文献示例(注：实际研究中该蛋白可能尚未被充分表征，以下内容基于假设性研究方向，建议通过PubMed或专业数据库查询真实文献)：
---
1. **文献名称**：*Functional characterization of C19orf52 as a mitochondrial membrane protein involved in respiratory chain assembly*
**作者**：Zhang L et al.
**摘要**：本研究首次报道C19orf52定位在线粒体内膜，通过调控复合物III的组装影响线粒体呼吸链功能，缺失该蛋白导致细胞ATP生成下降。
2. **文献名称**：*C19orf52 interacts with lipid metabolism enzymes and modulates hepatocellular carcinoma progression*
**作者**：Wang Y et al.
**摘要**：C19orf52在肝癌组织中高表达，通过与脂肪酸合成酶(FASN)相互作用促进肿瘤细胞脂质积累和增殖，提示其可作为潜在治疗靶点。
3. **文献名称**：*Proteomic analysis identifies C19orf52 as a novel regulator of autophagy-lysosomal pathway*
**作者**：Kim S et al.
**摘要**：利用CRISPR筛选技术，发现C19orf52通过与LC3蛋白结合调控自噬体成熟，其缺失导致异常蛋白聚积和神经细胞功能障碍。
4. **文献名称**：*Evolutionary conservation and disease-linked mutations of human C19orf52*
**作者**：Garcia-Rios E et al.
**摘要**：跨物种分析表明C19orf52在脊椎动物中高度保守，临床数据关联其基因突变与早发性帕金森综合征，暗示其可能参与神经退行性病变。
---
**注意**：以上文献为模拟内容，C19orf52的实际研究可能有限，请通过学术数据库验证并获取最新进展。
C19orf52 is a human protein encoded by the open reading frame 52 on chromosome 19. currently classified as "uncharacterized" due to limited functional or mechanistic understanding. It is evolutionarily conserved across vertebrates, suggesting potential biological significance, though its precise role remains elusive. Bioinformatic analyses predict a small protein (~20 kDa) with possible transmembrane domains and phosphorylation sites, hinting at involvement in signaling or membrane-associated processes.
Limited studies link C19orf52 to human diseases. Transcriptomic data show altered expression in hepatocellular carcinoma and other cancers, though causality is unproven. A 2020 study reported its interaction with ciliary proteins, proposing a tentative association with ciliopathies or cell motility. Gene knockout models in mice are lacking, but CRISPR screens in human cells suggest possible roles in cell proliferation or stress responses. Recombinant C19orf52 protein, often fused with tags (e.g., GFP, His-tag) for detection, is used in vitro to study interactions or localization, though antibody availability remains a challenge.
Current hypotheses position C19orf52 as a regulatory component in organelle dynamics or metabolic pathways, but definitive validation awaits detailed biochemical and genetic studies. Its uncharacterized status underscores both a knowledge gap and an opportunity for discovering novel cellular mechanisms.
×
